| Literature DB >> 32569377 |
Payal Patel1, Parth Patel2, Meha Bhatt3, Cody Braun4, Housne Begum3, Robby Nieuwlaat3, Rasha Khatib5, Carolina C Martins3, Yuan Zhang3, Itziar Etxeandia-Ikobaltzeta3, Jamie Varghese2, Hani Alturkmani2, Waled Bahaj2, Mariam Baig2, Rohan Kehar6, Ahmad Mustafa2, Rakesh Ponnapureddy2, Anchal Sethi2, Merrill Thomas2, David Wooldridge2, Wendy Lim7,8, Shannon M Bates7,8,9, Eddy Lang10, Grégoire Le Gal11, Marc Righini12, Wojtek Wiercioch3, Holger J Schünemann3,7, Reem A Mustafa3,13.
Abstract
After deep vein thrombosis (DVT) is diagnosed, prompt evaluation and therapeutic intervention are of paramount importance for improvement in patient-important outcomes. We systematically reviewed patient-important outcomes in patients with suspected DVT, including mortality, incidence of pulmonary embolism (PE) and DVT, major bleeding, intracranial hemorrhage, and postthrombotic sequelae. We searched the Cochrane Central Register of Controlled Trials, Ovid Medline, Embase for eligible studies, references lists of relevant reviews, registered trials, and relevant conference proceedings. Two investigators screened and abstracted data. Nine studies with 5126 patients were included for lower extremity DVT. Three studies with 500 patients were included for upper extremity DVT. Among patients with lower extremity DVT, 0.85% (95% confidence interval [CI], 0% to 2.10%) and 0% developed recurrent DVT and PE, respectively, at 3 months. Among patients with upper extremity DVT, 0.49% (95% CI, 0% to 1.16%) and 1.98% (95% CI, 0.62% to 3.33%) developed recurrent DVT and PE, respectively, at 3 months. No major bleeding events were reported for those anticoagulated, which is lower than in other systematic reviews. For both upper and lower extremity DVT, low pretest probability patients with a negative D-dimer had a comparable incidence of VTE at 3 months (∼1%) as patients with a negative ultrasound (US). At higher pretest probabilities, negative US testing with or without serial US appears to be the safer option. In this review, we summarized the outcomes of patients evaluated by various diagnostic pathways. In most instances, there was significant limitation due to small population size or lack of direct evidence of effects of using a specific pathway. This systematic review was registered at PROSPERO as CRD42018100502.Entities:
Mesh:
Year: 2020 PMID: 32569377 PMCID: PMC7322950 DOI: 10.1182/bloodadvances.2020001558
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529